 evalu combin thrombolyt therapi time cardiac catheter acut myocardi infarct result thrombolysi angioplasti myocardi infarct phase trial tami studi group recent trial myocardi reperfus single-ag thrombolyt therapi sequenti cardiac catheter conserv approach patient acut myocardi infarct combin thrombolyt therapi role untest strategi aggress use cardiac catheter multicent clinic trial factori design patient drug regimen tissue-typ plasminogen activ t-pa urokinas catheter strategi immedi catheter angioplasti fail thrombolysi predischarg catheter day patient contraind thrombolyt therapi cardiogen shock age year global ventricular eject fraction ident predischarg catheter catheter thrombolyt strategi combin thrombolyt therapi complic clinic cours rate reocclus urokinas t-pa rate recurr ischemia urokinas t-pa composit clinic end point death stroke reinfarct reocclus heart failur recurr ischemia combin thrombolyt therapi freedom advers event singl agent urokinas t-pa complic clinic cours composit clinic end point clinic sever earli patenc rate combin therapi predischarg patenc rate intervent patenc similar drug regimen differ complic rate thrombolyt regimen aggress catheter strategi overal earli patenc rate predischarg patenc rate predischarg patenc conserv strategi aggress strategi region wall motion infarct region sds/chord defer catheter sds/chord patient aggress strategi free advers outcom conserv strategi clinic cours complic advers outcom sever signific increas use blood product aggress strategi abstract truncat AT word